The fully automated Idylla™ ctEGFR Mutation Assay (RUO) is fast and easy to perform and can be used to determine the EGFR mutation status using liquid biopsy plasma samples. The Idylla™ ctEGFR Mutation Assay covers 49 EGFR mutations in exons 18, 19, 20 & 21 and showed high concordance compared to NGS1. Additionally, one of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed.
In a feasibility study comparing Idylla™ ctEGFR Mutation Assay* to NGS, the Idylla™ ctEGFR Mutation Assay* shows high concordance and ease of use combined with fast turnaround time for the testing of 49 relevant EGFR mutations in 2 ml of NSCLC plasma samples1.
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1-2 ml of plasma.